VivoSeq
Nephrology

Renal Impairment

2

Pipeline Programs↗

16

Active Trials↗

94

Companies Involved↗

Renal Impairment is an early-stage landscape with 2 programs across 94 companies. The most active players are AstraZeneca, Shionogi, CSPC ZhongQi Pharmaceutical Technology Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

36/100

Pipeline Velocity

42/100

Mech. Concentration

N/A

Completion Rate

93/100

Attrition Rate

6/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

1 program

Phase 1Shionogi logo

Shionogi

1 program

Phase 1CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

1 program

Phase 1J

Jiangsu vcare pharmaceutical technology co., LTD

1 program

Phase 1Merck & Co. logo

Merck & Co.

0 programs

PreclinicalNovartis logo

Novartis

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 12

Opemalirsen (AZD2373)

AstraZeneca

S-892216-PO

Shionogi

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

266

clinical trials

Completed228 · 86%
Terminated16 · 6%
Recruiting13 · 5%
Unknown status5 · 2%
Not yet recruiting2 · 1%
Active, not recruiting1 · 0%
Other1 · 0%

Clinical Trials

Trial Activity

266 trials

Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function
Recruiting·AAligos Therapeutics·Phase 1·NCT07342881·30 enrolled
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
Recruiting·Eli Lilly logoEli Lilly·Phase 1·NCT07426380·28 enrolled
A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment
Recruiting·SServier Bio-Innovation LLC·Phase 1·NCT07006688·30 enrolled
Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Renal Impairment and Normal Renal Function
Recruiting·GGan & Lee Pharmaceuticals.·Phase 1·NCT07141030·32 enrolled
Pharmacokinetics and Safety of Rupatadine in Participants With Renal Impairment Compared to Control Participants
Recruiting·NNoucor Health S.A.·Phase 1·NCT06708520·48 enrolled
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
Recruiting·Mmedac GmbH·Phase 1·NCT05534620·36 enrolled
Effect of Renal Impairment on Enpatoran Pharmacokinetics
Recruiting·Merck & Co. logoMerck & Co.·Phase 1·NCT06589713·40 enrolled
Indigotindisulfonate Sodium as an Aid in Determination of Ureteral Patency in Patient's With Renal Impairment
Recruiting·PProve pharm·Phase 4·NCT06085183·48 enrolled
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
Recruiting·Taiho Oncology, Inc. logoTaiho Oncology, Inc.·Phase 1·NCT04953897·18 enrolled
A Pharmacokinetic Study of VCT220 With Moderate Renal Impairment Patients
Recruiting·VVincentage Pharma Co., Ltd·Phase 1·NCT07347808·16 enrolled
A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment
Recruiting·QQpex Biopharma, Inc.·Phase 1·NCT07104162·40 enrolled
A Single-Center, Non-Randomized, Open-Label, Parallel-Group Phase I Clinical Trial to Evaluate the Pharmacokinetic Characteristics of Multiple Doses of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Moderate Renal Impairment and Normal Renal Function
Recruiting·CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logoCSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT07694869·16 enrolled
Pharmacokinetics of VC005 Tablets in Subjects With Renal Impairment and Normal Renal Function
Recruiting·JJiangsu vcare pharmaceutical technology co., LTD·Phase 1·NCT07551570·32 enrolled
A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment
Active, not recruiting·Eli Lilly logoEli Lilly·Phase 1·NCT07165015·32 enrolled
Optimizing Linezolid Dosing in Patients With Advanced Renal Impairment: a Therapeutic Drug Monitoring-based Evaluation
Not yet recruiting·—·Phase 4·NCT07138521·50 enrolled
Page 1 of 18

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)